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Abstract To investigate the effects of recombinant human
endostatin Endostar on metastasis and angiogenesis and
lymphangiogenesis of colorectal cancer cells in a mouse
xenograft model. Colon cancer cells SW620 were injected
subcutaneously into the left hind flank of nude mice to
establish mouse xenograft models. The mice were treated
with normal saline or Endostar subcutaneously every other
day. The growth and lymph node metastasis of tumor cells,
angiogenesis and lymphangiogenesis in tumor tissue were
detected.Apoptosisandcellcycledistributionwerestudiedby
flow cytometry. The expression of VEGF-A, -C, or -D in
S W 6 2 0c e l l sw a sd e t e r m i n e db yi m m u n o b l o t t i n ga s s a y s .
Endostar inhibited tumor growth and the rate of lymph node
metastasis (P<0.01). The density of blood vessels in or
around the tumor area was 12.27±1.21 and 22.25±2.69 per
field in Endostar-treated mice and controls (P<0.05),
respectively. Endostar also decreased the density of lym-
phatic vessels in tumor tissues (7.84±0.81 vs. 13.83±1.08,
P<0.05). Endostar suppresses angiogenesis and lymphangio-
genesis in the lymph nodes with metastases, simultaneously.
The expressionofVEGF-A, -Cand -D inSW620 cells treated
with Endostar was substantially lower than that of controls.
Endostar inhibited growth and lymph node metastasis of
colon cancer cells by inhibiting angiogenesis and lymphan-
giogenesis in a mouse xenograft model of colon cancer.
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Colorectal cancer is the third most frequent cancer worldwide
after breast and lung cancers and is also one of the most
commoncausesofcancerdeathworldwide,rankingsecondas
the most fatal malignancy in developed countries. The impact
of this disease is staggering worldwide: the annual incidence
of colorectal cancer has been on the rise in many countries
except the USA [1]. Conventional therapies including
surgery, chemotherapy or radiotherapy have been proven to
be relatively ineffective [2]. The main reasons for these
unsuccessful therapies are regional lymph node and/or distal
metastasis of colorectal cancer cells [3]. Approximately one
quarter of colorectal cancer patients present with metastatic
disease at the time of diagnosis and their five-year survival
rates are approximately 10% [4]. However, the mechanisms
underlying this malignancy still remain largely unknown.
For this reason, elucidating cellular factors involved in the
metastatic cascade is a key goal for developing therapeutic
agents to reduce colorectal cancer-associated mortality.
Dependence of tumor growth and metastasis on blood
vessels makes angiogenesis a fundamental hallmark of
cancer. Angiogenesis occurs in the microenvironment of
many solid tumors including colorectal cancer [5] and is
driven by multiple factors such as basic fibroblast growth
factor and vascular endothelial growth factor (VEGF)-A,
which are essential for the growth and metastasis of
colorectal cancer [5, 6]. For this reason, anti-angiogenic
therapy has emerged as a therapeutic option for malignant
diseases. Agents targeting directly at VEGF-A, such as
bevacizumab, have become part of the standard regimen for
metastatic colorectal cancer. Several researches indicated an
advantage in favor of the addition of bevacizumab to
chemotherapy in terms of overall survival, progression-free
survival and response rate [7]. However, the development
of bevacizumab-resistant tumors has become more common
since its integration into the treatment of cancers [8].
Furthermore, some side effects attributable to bevacizumab
therapy were reported to date [9].
Lymphangiogenesis, in addition to angiogenesis, also
occurs in colorectal cancer [10, 11]. The density of
lymphatic vessels in or surrounding tumors is closely
associated with lymph node metastasis and prognosis of
colorectal cancer patients [12, 13]. The best validated
molecular signaling system for tumor lymphangiogenesis
involves VEGF-C and VEGF-D, which induce the growth
of lymphatic vessels by activating VEGF receptor-3
(VEGFR-3) on the surface of lymphatic endothelial cells
[14]. Thus, anti-lymphangiogenesis therapy may be another
attractive anticancer treatment strategy [15, 16]. While anti-
lymphangiogenesis is not tested clinically yet, tailored
treatments consisting of combinations of chemotherapy,
anti-angiogenesis, and anti-lymphangiogenesis agents will
hopefully improve patient outcomes. Interestingly, endostatin,
a broad-spectrum endogenous inhibitor of angiogenesis,
which inhibits the proliferation of endothelial cells, inhibits
both lymphangiogenesisin tumorsandlymphnodemetastasis
of tumor cells simultaneously [17–19].
Previous studies have suggested that plasma endostatin
levels are elevated in colorectal cancer patients with liver
metastases [20]. Endostatin inhibited not only colon cancer
growth in vitro and in vivo, but also reduced colorectal
cancer cell adhesion in the liver sinusoids during the very
early phases of metastasis formation in a liver metastasis
mouse model [21, 22]. Because endostatin is naturally
occurring, and its half-life is short, there have been
numerous attempts to modify endostatin, with some
successes. Endostar, a novel recombinant human endo-
statin, is purified in E. coli with an additional nine-amino
acid sequence that forms a His-tag structure. Endostar has
been approved by the State Food and Drug Administration
of China (SFDA) for the treatment of non-small cell lung
cancer in 2005 [23]. More recently, it has been shown that
Endostar combined with oxaliplatin inhibited growth and
induced apoptosis in a human colorectal carcinoma model
[24]. However, it is not clear whether Endostar inhibits the
lymphangiogenesis or metastasis of colorectal cancer.
In the present study, we used a colon cancer xenograft
mouse model to evaluate the effect of Endostar on tumor
progression, angiogenesis or lymphangiogenesis of colorectal
cancer. We find that Endostar inhibited both the growth and
lymph node metastasis of colorectal cancer by inhibiting the
angiogenesis and lymphangiogenesis in a mouse xenograft
model of colon cancer. Our current work provides a new
prospect for targeted therapy of colorectal cancer.
Materials and Methods
Cell Line and Animals
Luciferase-expressing human colon cancer cell line SW620,
a gift from Longmed Inc. (United States (US)), was
maintained in Minimum Essential Medium (Gibco, Grand
Island, NY) supplemented with 10% fetal bovine serum at
37°C in a humidified atmosphere containing 5% CO2.
Fiveto6weekoldmalenudemice(BALB/cnu/nu),which
were purchased from the Institute of Laboratory Animal
Science, Chinese Academy of Medical Sciences, Beijing,
China, were housed in environmentally controlled conditions
(22°C,a12-hlight/darkcyclewiththelightcyclefrom6:00to
18:00 and the dark cycle from 18:00 to 6:00) with ad libitum
access to standard laboratory chow. The study protocol was
approved by the local Institution Review Board and animal
experiments were conducted in accordance with the guideline
of the local Institutional Animal Care and Use Committee,
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and Accreditation of Laboratory Animal Care International.
Mouse Xenograft Study
SW620 cells were rendered into single-cell suspensions and 5
to 6×10
6 cells in 200 μL serum-free medium were injected
subcutaneously into the left hind flank of BALB/c mice.
Tumors were allowed to grow untreated until they reached
7 mm in diameter, and then the mice were randomly divided
into two groups (n=9). Group 1 (control group) was treated
with normal saline (NS) (200 μL for each mouse) by
subcutaneous injection around the tumor every other day.
Group 2 was treated with Endostar (purchased from Simcere
Pharmaceutical Co., Jiangsu, China) at 10 mg/kg by
subcutaneous injection around the tumor every other day.
All these treatments were maintained for four weeks. Tumor
growth and metastasis were monitored using the Xenogen
IVIS Imaging System (Xenogen, US). The mice underwent
initial imaging at one week post inoculation when the tumor
length reached approximately 7 mm in length. For in vivo
imaging, mice were administered D-luciferin (150 mg/kg)
(Promega, Madison, WI) by intraperitoneal injection. Fifteen
min later, photons from the whole animal body were counted
using the Xenogen IVIS system. Imaging was performed
once weekly. Data were analyzed using the Living Image
2.50 Software (Xenogen). In addition, one week after the
completion of the treatment regimen, all mice were weighed
and then sacrificed by application of chloral hydrate
anesthesia. A complete autopsy, including lymph node
dissection, was performed evaluated histopathologically for
the presence of metastases. The samples were routinely
sectioned and stained with hematoxylin and eosin (H&E) and
evaluated by two pathologists in a double-blinded manner.
Determination of Blood Vessel and Lymph Vessel Densities
Tissue sections were stained with anti-CD31 antibody (rat
anti-mouse monoclonal antibody, 1:200, eBioscience, US)
and anti-LYVE-1 antibody (rabbit anti-mouse polyclonal
antibody, 1:200, Upstate, US). Biotinylated anti-rat or
rabbit antibodies (Beijing Zhongshan Golden Bridge
Biological Technology CO., Beijing, China) were used as
secondary antibodies. Three or 4 fields per tumor or lymph
node with metastases were scored for microvessel and lymph
vessel elements at ×200 magnifications by two double-
blindedobservers,andmicrovesselandlymphvesseldensities
in tumor or positive lymph nodes were calculated.
Western Blotting
SW620 cells were treated with 10 μg/mL Endostar and
24 h post treatment cellular lysates were prepared as
previously described [12]. Immunoblotting study was
performed as previously depicted [13] and the following
antibodies were used: anti-VEGF-A (rabbit anti-human
polyclonal antibody, 1:100, Santa Cruz, US), VEGF-C
(goat anti-human monoclonal antibody, 1:100, BioVision,
US), VEGF-D (mouse anti-human monoclonal antibody,
1:100;SantaCruz,US)orβ-actin(SantaCruzBiotechnology)
antibodies. The immunoblots were analyzed and quantified
by MCID imaging software (Imaging Research Inc., St.
Catharines, Ontario, Canada). The expression of VEGF-A, -C
and -D was normalized against β-actin.
Statistical Analysis
Differences in metastasis formation between groups were
analyzed using the χ
2 test and confirmed with Fisher’se x a c t
test. The other data were expressed as the mean ± standard
deviation (x  s). One-way analysis of variance (ANOVA)
was used to assess the statistical significance of differences
between groups using SPSS 15.0 software. P<0.05 was
considered statistically significant.
Results
During the treatment regimen, one mouse in the control group
died. All of the other mice survived until the experiment was
completed.
Endostar Inhibits Metastasis of Tumor Cells to Regional
Lymph Nodes
To evaluate the effect of Endostar on regional lymph node
metastasis of colorectal cancer cells, we established a
mouse xenograft model of colorectal cancer using the
human colon cancer cell line SW620, which has a high
frequency of lymph node metastasis. Using the Xenogen
IVIS Imaging System, we observed early indication of
metastasis to the lymph nodes in the axilla and groin region
4 weeks after inoculation of SW620 cells into the control
mice (Fig. 1a). On the other hand, we detected photons in
lymph nodes in the axilla and groin region in only 3 out 9
of Endostar-treated mice (Fig. 1b). Quantification of the
amount of photons emitted by luciferase expressing tumors
showed that, compared with that of the control group, the
amount of photons emitted by luciferase expressing tumors
in mice receiving Endostar was markedly decreased from
week 3 post tumor implantation (Fig. 1c)( P<0.05).
Furthermore, examination of lymph nodes in the axilla
and groin region of sacrificed mice at week 6 post tumor
cell inoculation revealed that tumor cells metastasized to
the lymph nodes in 33.3% (3/9) of Endostar-treated mice
while all the mice in the control group showed metastasis to
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(Fig. 2a and b)( P<0.01), which was confirmed by the
presence of tumor cells in the enlarged lymph nodes in
H&E-stained tissue sections (Fig. 2c). In addition, we
determined the number of tumor positive lymph nodes in
mice with lymph node metastasis. We found only 4 lymph
nodes with metastasis in the 3 animals with lymph node
positive in Endostar-treated group animals. The average
number of metastatic lymph nodes per node-positive mouse
in the Endostar-treated group was significantly smaller than
that in the control group (1.33±0.57 vs 2.63±0.7, P<0.05)
(Table 1). These results indicated that Endostar could suppress
the metastasis of colon cancer cells in mice bearing human
colon cancer xenograft.
Fig. 1 The activity and metastasis of tumor cells as evaluated by
Xenogen IVIS Imaging System in vivo (a): the control group; (b): the
Endostar group; (c): Growth curve of tumors on the nude mice model
of human colon cancer. Tumor growth was inhibited significantly in
the Endostar group than in the control group (P<0.05)
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To investigate the effect of Endostar on tumor neoangio-
genesis, we examined the tissue sections by immunohisto-
chemical staining with anti-CD31antibody to visualize tumor
blood vessels in the control mice (Fig. 3a) and in the mice
bearing human colon cancer xenograft treated with Endostar
(Fig. 3b). The average number of blood vessels in the tumor
area per visual field was 22.25±2.69 in the control
xenografts and 12.27±1.21 in the xenograft treated with
Endostar group and control group, respectively (P<0.05)
(Fig. 3e). We further examined the number of lymphatic
vessels by immunohistochemical staining with anti-LYVE-1
antibodies to visualize tumor lymphatic vessels in the control
mice and in the mice bearing human colon cancer xenograft
treated with Endostar. The density of lymphatic vessels in the
tumor area per visual field was 13.83±1.08 in the control
group and 7.84±0.81 in the xenograft treated with Endostar
group, respectively (P<0.05) (Fig. 3f). Several expanded
lymphatic vessels were also observed within or around the
tumors in the control group and tumor thrombus were
observed in some of those expanded lymphatic vessels. In
contrast,mostLYVE-1positivevessels werestripe-likeinmice
treated with Endostar (Fig. 3c and d). Our data demonstrated
that Endostar could inhibit both angiogenesis and lymphan-
giogenesis in a mouse xenograft model of colon cancer.
The vessel numbers in the positive lymph nodes were also
measured. The density of blood vessels in Endostar-treat
group were remarkably reduced compared to the control
group (17.24±2.31 vs 9.63±1.87, P<0.05). A significant
reduction in intratumor lymphatic vessels density was
observed in mice that received Endostar therapy when
compared with animals in the control group (8.43±1.25 vs
3.54±1.07, P<0.05), suggested that Endostar can be
functional within the whole body.
Expression of VEGF-A, VEGF-C and VEGF-D in SW620
Cells
VEGF-A, -C and -D expression has been correlated with
the growth of lymphatic vessels. In order to unveil how
Endostar inhibited lymphangiogenesis, we investigated the
effect of Endostar on the expression of VEGF-A, -C and D
in SW620 cells by immunoblotting using anti-VEGF
antibodies. We found that Endostar treatment noticeably
decreased the levels of VEGF-A, -C and -D. The level of
VEGF-A in SW620 cells treated with Endostar was 2.37-
fold lower than that of controls and the level of VEGF-C
and VEGF-D in SW620 cells treated with Endostar was
Fig. 2 Gross and histological appearance of primary SW620 colon cancer and lymph node metastasis. Grossly enlarged regional lymph node of
the inguina (a) and axilla (b) (arrow); H&E-staining of the metastatic tumor in the lymph node (C) (×100)
Table 1 Effect of Endostar on lymph node metastasis in mouse xenograft model of colorectal cancer
No. of mice No. of node- positive mice
a No. of positive lymph nodes
b
Control 8 8 (100%) 2.63±0.7 (n=8)
Endostar 9 3 (33.3%) 1.33±0.57 (n=3)
P value <0.01 <0.05
aMetastasis to the regional lymph nodes was detected by histological examination.
bMean ± SEM of the number of metastatic lymph nodes per mouse.
Recombinant Human Endostatin Endostar 3191.18-fold and 1.49-fold lower than that of controls,
respectively (Fig. 4). These results suggested that Endostar
could inhibit the angiogenesis and lymphangiogenesis of
human colon cancer cells by downregulating the expression
of VEGF-A,-C,-D.
Discussion
Nowadays, colorectal cancer is one of the most common
causesofmalignanttumormortalityworldwide.Mostofthese
deaths occur in patients with locally advanced colorectal
Fig. 3 CD31-positive blood vessels and LYVE-1-positive lymphatic
vessels in tumor tissue. a: Several expanded blood vessels were within
the tumors in the control mice (×200). b: The blood vessels were
stripe like in Endostar-treated mice (×200). c: Several expanded
lymphatic vessels with tumor thrombus (arrows) were also observed
within and around the tumors in the control mice (×200). d: Most
LYVE-1 positive vessels were stripe-like in mice treated with
Endostar(×200). Bar=50 μm. e: The microvessel density (MVD) in
Endostar-treated mice was markedly lower than that in the control
group (P<0.05). f: The microlymphatic vessel density (MLD) in the
Endostar group was markedly lower than that in control group (P<0.05)
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colorectal cancer has been decreasing over the previous two
decadesinWesterncountries,itsincidencerateisontherisein
the Eastern hemispheres [25, 26]. Unfortunately the common
therapeutic regimen for colorectal cancer, including surgery,
chemotherapy and radiation, are insufficient to eliminate the
tumor burden and colorectal cancer continues to inflict a
heavy toll worldwide. Therefore, there is an urgent need to
develop novel therapeutic approaches for combating this
devastating disease.
Angiogenesis is essential for the development, growth and
advancement of solid tumors, including those associated with
colorectal cancer. Recently, anti-angiogenic therapy has
emerged as a treatment of malignant disease [27]. However,
the genomic instability and heterogeneity of tumor cell
populations lead to a shift of the expression of angiogenic
factors during tumor progression. Various tumors at their
advanced stage express multiple angiogenic factors [5]. At
this stage, anti-VEGF-A monotherapy such as bevacizumab
would be predicted to be ineffective or even encounter drug
resistance. Furthermore, anti-VEGF-A monotherapy might
even help tumors to switch on other angiogenic pathways for
angiogenesis [28]. As a result, tumors can escape from anti-
VEGF-A therapy after a relative long-term treatment [29].
Additionally, these drugs can increase some side effects such
as rash, diarrhea, hypertension, even gastrointestinal perfo-
ration and arterial thromobembolic events [7, 8]. It is
therefore necessary to find the new target therapy to treat
colorectal cancer.
Endostatin is another important angiogenesis inhibitor,
and it is one of the most potent of the known inhibitors of
tumor angiogenesis. Many published reports showed that
endostatin mainly suppresses pathological angiogenesis by
downregulating a number of angiogenic factors, including
VEGF-A and FGF-2, and produces virtually no toxicity
after long-term delivery [30, 31]. Endostar is a novel
recombinant human endostatin. The current data revealed
that Endostar exerts anti-angiogenic effects via a similar
mechanism as endostatin. However, Endostar differs from
endostatin in that it has an additional nine-amino acid
sequence with zinc binding activity that increases Endostar’s
half-life [32].
Using the noninvasive Xenogen in vivo imaging system,
we found that Endostar inhibited not only tumor growth,
but also lymph node metastasis in a mouse xenograft
model, which was confirmed by pathological examination
at the end of the experiment. This imaging system relies on
the measurement of luminescence produced by tumor cells
engineered to express luciferase, which is used as a way to
evaluate viability of tumor cells. Thus, the Xenogen system
provides a more accurate indication of anti-tumor activity
and anti-metastasis effect of Endostar than measurement of
tumor volume or the examination of the axilla and groin
area lymph nodes [33].
Previous studies have demonstrated that lymph node
metastasis is an independent prognostic factor for
malignant tumors [34, 35]. However, it is difficult to
prevent lymph node metastasis completely using the
current treatments for colorectal cancer. Our findings
indicated that Endostar may reduce the possibility of
tumor cells entering into the lymph nodes. Endostar
should ideally be administered at early stage in order to
reduce the spread of colorectal cancer cells to regional
lymph node, i.e. before the induction of lymphangio-
genesis in tumor progression.
In order to elucidate the mechanism whereby Endostar
inhibited lymphangiogenesis, we investigated the effect of
Endostar on the expression of VEGF-C and VEGF-D in
vitro. We showed that Endostar suppressed the expression
of these factors. However, this result did not agree with
findings from previous studies completely, which demon-
strated that endostatin inhibits lymphangiogenesis and
lymph node metastasis by downregulating VEGF-C rather
than VEGF-D expression in gastric cancer or skin tumor
tissues [17, 18]. Therefore, Endostar maybe differ from
endostatin in regulating lymphangiogenesis in different
types of tumors. It has been reported that both VEGF-C
and VEGF-D are upregulated in colorectal cancer, and both
of them not only increase the density but also induce the
enlargement of lymphatic vessels, which leads to metastasis
to regional lymph nodes [14]. Although the role of VEGF-D
in lymphangiogenesis is still relatively inconclusive, most
researchers believe that VEGF-D is at least a predictor for
lymphatic metastasis, or an independent prognostic factor
[36, 37].
In summary, Endostar inhibits not only angiogenesis, but
also lymphangiogenesis and lymph node metastasis, by
inhibiting the expressions of VEGF-A, VEGF-C and
VEGF-D in colorectal cancer. Our findings thus provide a
new strategy to develop novel treatments for colorectal
cancer.
Fig. 4 VEGF-A, -C, and -D protein expression levels in SW620 cells
detected by Western blotting analysis. Endostar downregulated the
expression of VEGF-A,-C,-D in SW620 cells in vitro
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